Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Inhibitors in the Treatment of Cancer and Neurodegenerative Disorders"
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: 30 June 2023 | Viewed by 590
Special Issue Editors
Interests: drug design; medicinal chemistry; epigenetic inhibitors; multitarget ligands
Interests: immunomodulation; pathogenic mechanisms of autoimmune diseases
Interests: medicinal chemistry; drug design; epigenetic inhibitors
Special Issue Information
Molecular mechanisms that underpin the onset and progression of malignant and neurodegenerative diseases seem to have little in common. Some epidemiological studies add weight to the inverse association between certain types of cancer and neurodegenerative diseases. However, there is no clear consensus on this connotation. Cancer cells escape cell death signals whereas aberrant activation of neuronal cell death is a common hallmark in neurodegenerative diseases. Numerous studies suggest common genetic and epigenetic factors that are implicated in cancer and neurodegeneration. Some of these include p53, ATM gene, Cyclin-dependent kinase 5 (CDK5), glycogen synthase kinase-3 (GSK3), histone deacetylase 2 (HDAC2), Brain-derived Neurotrophic Factor (BDNF), changes in microRNA (miRNA) expression and many more.
To improve our understanding of the crosstalk between cancer and neurodegeneration, this Special Issue aims to discuss the novel therapeutic agents able to target aberrant molecular mechanisms common in cancer and neurodegenerative diseases.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Identification of prognostic markers for cancer and neurodegeneration
- Identification of novel drug targets and signaling molecules
- Repurposing of drug treatments for cancer and neurodegeneration
- Drug design of novel compounds targeting cancer and neurodegeneration
We look forward to receiving your contributions.
Prof. Dr. Katarina Nikolic
Prof. Dr. Biljana Bufan
Dr. Dusan Ruzic
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- drug design
- parkinson disease
- multiple sclerosis
- novel small-molecule inhibitors